Is SLS up or down today?
SLS is up 1.17% today, last at 13.86. This stock moved +1.17% versus the prior close.
SLS · SLS
SLS (SLS) is trading at 13.86, up 1.17% on the session. SLS sits at the 86% mark of its 52-week range, carries a 14-day RSI of 55, and trades above its 50-day average. Over the past month it is up 18.46%.
Leading the coverage: “SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’” (Stocktwits, 4d ago). SLS is +3.90% since story.
SLS trades on a trailing P/E of 12.1 and is running 18.25% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
SLS is up 1.17% today, last at 13.86. This stock moved +1.17% versus the prior close.
Leading the coverage: “SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’” (Stocktwits, 4d ago). SLS is +3.90% since story. Dominant story: SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate (5 sources, neutral) RSI is 55 — neutral Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (127 days) · Drag or scroll left for earlier dates
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here